Literature DB >> 19352137

Clinical experience with the combined use of lopinavir/ritonavir and rifampicin.

Rafaëlla Fa L'homme1, Hanneke M J Nijland, Luuk Gras, Rob E Aarnoutse, Reinout van Crevel, Martin Boeree, Kees Brinkman, Jan M Prins, Job R Juttmann, David M Burger.   

Abstract

Thirty-four patients treated concomitantly with lopinavir/ritonavir and rifampicin were evaluated. Overall, only 15% used the recommended increased dose of lopinavir/ritonavir. Of patients on a nonadjusted dose of lopinavir/ritonavir, 67% had a subtherapeutic lopinavir plasma concentration and 38% had a detectable viral load. Forty percent of patients on an increased dose of lopinavir/ritonavir prematurely stopped the drug combination because of adverse events. Combined use of lopinavir/ritonavir and rifampicin is challenging as it implies balancing between suboptimal efficacy and toxicity.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19352137     DOI： 10.1097/QAD.0b013e328329148e

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  16 in total

Review 1.  The challenge of new drug discovery for tuberculosis.

Authors:  Anil Koul; Eric Arnoult; Nacer Lounis; Jerome Guillemont; Koen Andries
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

2.  CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir.

Authors:  Feng Li; Jie Lu; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2011-09-27       Impact factor: 3.922

Review 3.  Initiating antiretrovirals during tuberculosis treatment: a drug safety review.

Authors:  Tanuja N Gengiah; Andrew L Gray; Kogieleum Naidoo; Quarraisha Abdool Karim
Journal:  Expert Opin Drug Saf       Date:  2011-01-05       Impact factor: 4.250

4.  Tuberculosis drug development: ensuring people living with HIV are not left behind.

Authors:  Anne F Luetkemeyer; Haileyesus Getahun; Gabriel Chamie; Christian Lienhardt; Diane V Havlir
Journal:  Am J Respir Crit Care Med       Date:  2011-08-25       Impact factor: 21.405

Review 5.  Tuberculosis and HIV co-infection: screening and treatment strategies.

Authors:  Kartik K Venkatesh; Soumya Swaminathan; Jason R Andrews; Kenneth H Mayer
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

6.  Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa.

Authors:  Julie H Levison; Catherine Orrell; Elena Losina; Zhigang Lu; Kenneth A Freedberg; Robin Wood
Journal:  Antivir Ther       Date:  2011

7.  Loss to follow-up and mortality among HIV-infected people co-infected with TB at ART initiation in Durban, South Africa.

Authors:  Ingrid V Bassett; Senica Chetty; Bingxia Wang; Matilda Mazibuko; Janet Giddy; Zhigang Lu; Rochelle P Walensky; Kenneth A Freedberg; Elena Losina
Journal:  J Acquir Immune Defic Syndr       Date:  2012-01-01       Impact factor: 3.731

8.  Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis.

Authors:  Bryan E Shepherd; Cathy A Jenkins; Deidra D Parrish; Tracy R Glass; Angela Cescon; Angels Masabeu; Genevieve Chene; Frank de Wolf; Heidi M Crane; Inma Jarrin; John Gill; Julia del Amo; Sophie Abgrall; Pavel Khaykin; Clara Lehmann; Suzanne M Ingle; Margaret T May; Jonathan A C Sterne; Timothy R Sterling
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

9.  Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.

Authors:  Richard A Murphy; Vincent C Marconi; Rajesh T Gandhi; Daniel R Kuritzkes; Henry Sunpath
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

10.  Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.

Authors:  Kevin Peterson; Sabelle Jallow; Sarah L Rowland-Jones; Thushan I de Silva
Journal:  AIDS Res Treat       Date:  2011-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.